Traders bought shares of Stryker Corp. (NYSE:SYK) on weakness during trading on Thursday after an insider sold shares in the company. $120.26 million flowed into the stock on the tick-up and $92.40 million flowed out of the stock on the tick-down, for a money net flow of $27.86 million into the stock. Of all equities tracked, Stryker Corp. had the 16th highest net in-flow for the day. Stryker Corp. traded down ($2.21) for the day and closed at $114.03Specifically, VP Yin C. Becker sold 1,111 shares of the business’s stock in a transaction dated Thursday, October 6th. The stock was sold at an average price of $117.00, for a total value of $129,987.00. Following the completion of the transaction, the vice president now owns 16,939 shares of the company’s stock, valued at approximately $1,981,863. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 12,000 shares of the business’s stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of $110.18, for a total value of $1,322,160.00. Following the completion of the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at approximately $21,280,385.56. The disclosure for this sale can be found here. 7.80% of the stock is owned by company insiders.

A number of brokerages have weighed in on SYK. Piper Jaffray Cos. boosted their target price on Stryker Corp. from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, July 22nd. Credit Suisse Group AG reissued an “outperform” rating and issued a $124.00 target price (up previously from $110.00) on shares of Stryker Corp. in a research report on Tuesday, July 19th. Brean Capital reaffirmed a “buy” rating and set a $125.00 price target (up previously from $121.00) on shares of Stryker Corp. in a research report on Monday, July 25th. Jefferies Group reaffirmed a “hold” rating and set a $120.00 price target (up previously from $113.00) on shares of Stryker Corp. in a research report on Monday, July 25th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $130.00 price target on shares of Stryker Corp. in a research report on Sunday, July 24th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating to the stock. Stryker Corp. currently has a consensus rating of “Hold” and a consensus price target of $121.27.

The stock has a market capitalization of $41.32 billion, a PE ratio of 25.12 and a beta of 0.86. The company’s 50-day moving average price is $115.24 and its 200-day moving average price is $114.92.

Stryker Corp. (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 27th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The firm earned $2.83 billion during the quarter, compared to analysts’ expectations of $2.81 billion. During the same period last year, the business posted $1.25 earnings per share. The company’s revenue for the quarter was up 17.1% compared to the same quarter last year. Analysts predict that Stryker Corp. will post $5.78 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Blue Chip Partners Inc. boosted its position in shares of Stryker Corp. by 0.3% in the second quarter. Blue Chip Partners Inc. now owns 1,757 shares of the medical technology company’s stock valued at $211,000 after buying an additional 6 shares in the last quarter. Washington Trust Bank boosted its position in shares of Stryker Corp. by 0.5% in the second quarter. Washington Trust Bank now owns 3,040 shares of the medical technology company’s stock valued at $364,000 after buying an additional 15 shares in the last quarter. Wetherby Asset Management Inc. boosted its position in shares of Stryker Corp. by 0.3% in the second quarter. Wetherby Asset Management Inc. now owns 6,242 shares of the medical technology company’s stock valued at $748,000 after buying an additional 18 shares in the last quarter. Douglas Lane & Associates LLC boosted its position in shares of Stryker Corp. by 0.7% in the second quarter. Douglas Lane & Associates LLC now owns 2,945 shares of the medical technology company’s stock valued at $353,000 after buying an additional 20 shares in the last quarter. Finally, Wade G W & Inc. boosted its position in shares of Stryker Corp. by 1.0% in the third quarter. Wade G W & Inc. now owns 2,230 shares of the medical technology company’s stock valued at $260,000 after buying an additional 22 shares in the last quarter. Institutional investors own 75.29% of the company’s stock.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.